Nateglinide: Difference between revisions

Nateglinide
	File:Nateglinide.svg
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Latest revision as of 01:45, 20 February 2025

An oral antidiabetic medication

Nateglinide is an oral antidiabetic drug used in the management of type 2 diabetes mellitus. It belongs to the class of medications known as meglitinides, which stimulate the pancreas to release insulin.

Mechanism of Action[edit]

Nateglinide works by closing the ATP-sensitive potassium channels in the beta cells of the pancreas. This action leads to the opening of calcium channels, resulting in an influx of calcium ions and subsequent release of insulin. The drug is particularly effective in controlling postprandial blood glucose levels.

Pharmacokinetics[edit]

Nateglinide is rapidly absorbed from the gastrointestinal tract and has a quick onset of action. It is metabolized primarily in the liver by the cytochrome P450 enzyme system, particularly CYP2C9 and CYP3A4. The drug has a short half-life, which minimizes the risk of hypoglycemia.

Clinical Use[edit]

Nateglinide is indicated for the treatment of type 2 diabetes mellitus in conjunction with diet and exercise. It is often used in combination with other antidiabetic agents such as metformin or thiazolidinediones.

Side Effects[edit]

Common side effects of nateglinide include:

Contraindications[edit]

Nateglinide is contraindicated in patients with:

Type 1 diabetes mellitus
Diabetic ketoacidosis
Known hypersensitivity to the drug

Administration[edit]

Nateglinide is administered orally, typically taken before meals to optimize its effect on postprandial glucose levels.

Related pages[edit]

Nateglinide

Nateglinide

@@ Line 1: / Line 1: @@
-{{intro}}
+{{Short description|An oral antidiabetic medication}}
-Nateglinide is an oral hypoglycemic agent and amino acid derivative that stimulates insulin secretion from the pancreas and is used in the therapy of [[type 2 diabetes]].
+{{Drugbox
+| verifiedfields = changed
+| verifiedrevid = 477002123
+| image = Nateglinide.svg
+| image2 = <!-- Another image if available -->
+}}
-{{livtox}}
+'''Nateglinide''' is an oral [[antidiabetic drug]] used in the management of [[type 2 diabetes mellitus]]. It belongs to the class of medications known as [[meglitinides]], which stimulate the [[pancreas]] to release [[insulin]].
-Nateglinide has been linked to rare instances of clinically apparent acute liver injury.
-{{moa}}
+==Mechanism of Action==
-Nateglinide (na teg' li nide) is an insulin secretagogue that is similar in action but different in structure from the sulfonylureas. It is a derivative of phenylalanine and stimulates insulin secretion by blocking ATP sensitive potassium channels in pancreatic beta-cells, causing cell membrane depolarization which results in calcium influx and insulin secretion. Nateglinide has been shown to reduce the postprandial increase in glucose in patients with [[type 2 diabetes]] and improve glycemic control. Nateglinide
+Nateglinide works by closing the [[ATP-sensitive potassium channel]]s in the [[beta cells]] of the [[pancreas]]. This action leads to the opening of [[calcium channels]], resulting in an influx of [[calcium ions]] and subsequent release of insulin. The drug is particularly effective in controlling [[postprandial blood glucose]] levels.
-{{fda}}
+==Pharmacokinetics==
-{{PAGENAME}} was approved for use in the United States in 2000.
+Nateglinide is rapidly absorbed from the [[gastrointestinal tract]] and has a quick onset of action. It is metabolized primarily in the [[liver]] by the [[cytochrome P450]] enzyme system, particularly [[CYP2C9]] and [[CYP3A4]]. The drug has a short half-life, which minimizes the risk of [[hypoglycemia]].
-{{use}}
+==Clinical Use==
-The current indications are for management of [[type 2 diabetes]] used in combination with [[diet]] and [[exercise]], with or without other oral [[hypoglycemic agents]]. Nateglinide is available generically and under the brand name Starlix in tablets of 60 and 120 mg.
+Nateglinide is indicated for the treatment of [[type 2 diabetes mellitus]] in conjunction with [[diet]] and [[exercise]]. It is often used in combination with other antidiabetic agents such as [[metformin]] or [[thiazolidinediones]].
-{{dose}}
+==Side Effects==
-The typical initial dose in adults is 120 mg three times daily before meals.
+Common side effects of nateglinide include:
+* [[Hypoglycemia]]
+* [[Upper respiratory tract infection]]
+* [[Dizziness]]
+* [[Joint pain]]
-{{se}}
+==Contraindications==
-Side effects of nateglinide include [[diarrhea]], [[nausea]], gastrointestinal upset, [[hypoglycemia]], [[dizziness]] and [[rash]].
+Nateglinide is contraindicated in patients with:
+* [[Type 1 diabetes mellitus]]
+* [[Diabetic ketoacidosis]]
+* Known hypersensitivity to the drug
-{{antidiabetic drugs}}
+==Administration==
-{{coststubd}}
+Nateglinide is administered orally, typically taken before meals to optimize its effect on postprandial glucose levels.
+==Related pages==
+* [[Type 2 diabetes mellitus]]
+* [[Insulin]]
+* [[Meglitinides]]
+* [[Hypoglycemia]]
+[[Category:Antidiabetic drugs]]
+[[Category:Meglitinides]]
+<gallery>
+File:Nateglinide.svg|Nateglinide
+</gallery>